Headquartered in New York, NY Fiscal year ends December NASDAQ: RPRX royaltypharma.com
Royalty Pharma plc, founded in 1996, buys biopharmaceutical royalties and funds innovation across the biopharmaceutical industry. Its counterparties range from academic institutions, research hospitals and non-profits to small and mid-cap biotech companies and large global pharmaceutical companies. Its portfolio entitles it to payments based directly on the top-line sales of marketed therapies. It holds royalties on more than 35 commercial products, including:
- Vertex's cystic fibrosis franchise (Trikafta/Alyftrek)
- GSK's Trelegy
- Biogen's Tysabri and Spinraza
- Roche's Evrysdi
- Astellas/Pfizer's Xtandi
- Johnson & Johnson's Tremfya
- AbbVie/J&J's Imbruvica
- Servier's Voranigo
- Gilead's Trodelvy
- Amgen's Imdelltra
- Alnylam's Amvuttra
It also holds royalties on 16 development-stage product candidates. Beyond buying existing royalties, the company provides R&D co-funding, development-stage funding, and structured capital such as senior secured term loans (for example, to Revolution Medicines). Recent additions include royalties on Zoryve, Mimrylo and cliramitug. The company completed the internalization of its external manager in May 2025, which eliminated the management fee. It returns capital through quarterly dividends and Class A share repurchases. Updated
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.…
The tech stock selloff in July surprised the market but not those investors who were paying attention. As far back as April, Goldman Sachs (NYSE:GS | GS Price Prediction) warned of the…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Tuesday's additional top analyst upgrades and downgrades were on Adobe, AstraZeneca, Best Buy, Chemours, Oracle, Royalty Pharma, Teva Pharmaceutical and Tractor Supply.
Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill, Corning, Microsoft, PepsiCo, QuantumScape, Range Resources, Spotify Technology, Texas Instruments, Visa and…
Thursday’s additional top analyst upgrades and downgrades included Royalty Pharma, Twitter, UPS and more.
24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week, including Disney, Cisco and McDonald's.
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five…
Shares of these recently public companies still offer aggressive investors outstanding entry levels, but most have not seen their lockup periods end. They are rated Buy across Wall Street and also offer…
Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.
Chris Lange 24/7 Wall St. has put together a preview of Cisco Systems, Nio, Occidental Petroleum and some of the other most anticipated quarterly reports due this week.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may…
Royalty Pharma plc, founded in 1996, buys biopharmaceutical royalties and funds innovation across the biopharmaceutical industry. Its counterparties range from academic institutions, research hospitals and non-profits to small and mid-cap biotech companies and large global pharmaceutical companies.
24/7 Wall St.'s 12-month price target for RPRX is $78.91, rated Buy. The Wall Street consensus target is $72.00. RPRX price prediction →
